Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3. https://doi.org/10.1038/s41572-020-00235-0.

Article  PubMed  PubMed Central  Google Scholar 

Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and pd-l1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619–30. https://doi.org/10.1200/jco.20.01055.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65. https://doi.org/10.1016/s1470-2045(20)30539-8.

Article  PubMed  CAS  Google Scholar 

Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the astrum-005 randomized clinical trial. JAMA. 2022;328:1223–32. https://doi.org/10.1001/jama.2022.16464.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cheng S, Evans WK, Stys-Norman D, Shepherd FA. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2007;2:348–54. https://doi.org/10.1097/01.Jto.0000263720.15062.51.

Article  PubMed  Google Scholar 

Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, version 4.2024, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:249–74. https://doi.org/10.6004/jnccn.2204.0023.

Article  PubMed  CAS  Google Scholar 

Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw. 2008;6:323–31. https://doi.org/10.6004/jnccn.2008.0027.

Article  PubMed  CAS  Google Scholar 

Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14:986–94. https://doi.org/10.1634/theoncologist.2009-0026.

Article  PubMed  CAS  Google Scholar 

Auclin E, Benitez-Montanez J, Tagliamento M, Parisi F, Gorria T, Garcia-Campelo R, et al. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. Lung Cancer. 2023;178:116–22. https://doi.org/10.1016/j.lungcan.2023.02.002.

Article  PubMed  CAS  Google Scholar 

Aroldi F, Middleton MR. Long-term outcomes of immune checkpoint inhibition in metastatic melanoma. Am J Clin Dermatol. 2022;23:331–8. https://doi.org/10.1007/s40257-022-00681-4.

Article  PubMed  Google Scholar 

Zhang H, Hu Y, Wu T, Chen Y, Yang B, Xie T. Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review. Front Immunol. 2023;14:1309055. https://doi.org/10.3389/fimmu.2023.1309055.

Article  PubMed  CAS  Google Scholar 

Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, et al. Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol. 2020;6:1606–10. https://doi.org/10.1001/jamaoncol.2020.2169.

Article  PubMed  PubMed Central  Google Scholar 

Robert C, Schadendorf D, Messina M, Hodi FS, O’Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19:2232–9. https://doi.org/10.1158/1078-0432.Ccr-12-3080.

Article  PubMed  CAS  Google Scholar 

Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression–implications for drug resistance. Nat Rev Clin Oncol. 2013;10:571–87. https://doi.org/10.1038/nrclinonc.2013.158.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019;25:389–402. https://doi.org/10.1038/s41591-019-0382-x.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–37. https://doi.org/10.1158/2159-8290.Cd-15-1545.

Article  PubMed  PubMed Central  Google Scholar 

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018;6:1093–9. https://doi.org/10.1158/2326-6066.Cir-17-0755.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Plazy C, Hannani D, Gobbini E. Immune checkpoint inhibitor rechallenge and resumption: a systematic review. Curr Oncol Rep. 2022;24:1095–106. https://doi.org/10.1007/s11912-022-01241-z.

Article  PubMed  Google Scholar 

Park R, Lopes L, Saeed A. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. Immunotherapy. 2020;12:1183–93. https://doi.org/10.2217/imt-2020-0103.

Article  PubMed  CAS  Google Scholar 

Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020;11:1927–33. https://doi.org/10.1111/1759-7714.13483.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865–71. https://doi.org/10.1001/jamaoncol.2020.0726.

Article  PubMed  Google Scholar 

Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer. 2014;110:1721–6. https://doi.org/10.1038/bjc.2014.126.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, et al. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2019-000144.

Article  PubMed  PubMed Central  Google Scholar 

Giaj Levra M, Cotté FE, Corre R, Calvet C, Gaudin AF, Penrod JR, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer. 2020;140:99–106. https://doi.org/10.1016/j.lungcan.2019.12.017.

Article  PubMed  Google Scholar 

Vauchier C, Auclin E, Barthélémy P, Carril-Ajuria L, Ryckewaert T, Borchiellini D, et al. REchallenge of NIVOlumab (RENIVO) or nivolumab-ipilimumab in metastatic renal cell carcinoma: an ambispective multicenter study. J Oncol. 2022;2022:3449660. https://doi.org/10.1155/2022/3449660.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Niki M, Nakaya A, Kurata T, Yoshioka H, Kaneda T, Kibata K, et al. Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget. 2018;9:32298–304. https://doi.org/10.18632/oncotarget.25949.

Article  PubMed  PubMed Central  Google Scholar 

Velimirovici MD, Feier CVI, Vonica RC, Faur AM, Muntean C. Efficacy and safety of atezolizumab as a PD-L1 inhibitor in the treatment of cervical cancer: